136 related articles for article (PubMed ID: 17440944)
1. ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy.
Ben-Yosef R; Starr A; Karaush V; Loew V; Lev-Ari S; Barnea I; Lidawi G; Shtabsky A; Greif Y; Yarden Y; Vexler A
Prostate; 2007 Jun; 67(8):871-80. PubMed ID: 17440944
[TBL] [Abstract][Full Text] [Related]
2. Reversion of human prostate tumorigenic growth by azatyrosine.
Benoit RM; Eiseman J; Jacobs SC; Kyprianou N
Urology; 1995 Sep; 46(3):370-7. PubMed ID: 7660512
[TBL] [Abstract][Full Text] [Related]
3. Transfected neu oncogene induces human prostate cancer metastasis.
Zhau HY; Zhou J; Symmans WF; Chen BQ; Chang SM; Sikes RA; Chung LW
Prostate; 1996 Feb; 28(2):73-83. PubMed ID: 8604395
[TBL] [Abstract][Full Text] [Related]
4. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
Lu S; Lee J; Revelo M; Wang X; Lu S; Dong Z
Clin Cancer Res; 2007 Oct; 13(19):5692-702. PubMed ID: 17908958
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells.
Guo C; Geverd D; Liao R; Hamad N; Counter CM; Price DT
J Urol; 2001 Aug; 166(2):694-8. PubMed ID: 11458119
[TBL] [Abstract][Full Text] [Related]
6. Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells.
Wu GJ; Peng Q; Fu P; Wang SW; Chiang CF; Dillehay DL; Wu MW
Gene; 2004 Mar; 327(2):201-13. PubMed ID: 14980717
[TBL] [Abstract][Full Text] [Related]
7. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
8. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo.
Casimiro M; Rodriguez O; Pootrakul L; Aventian M; Lushina N; Cromelin C; Ferzli G; Johnson K; Fricke S; Diba F; Kallakury B; Ohanyerenwa C; Chen M; Ostrowski M; Hung MC; Rabbani SA; Datar R; Cote R; Pestell R; Albanese C
Cancer Res; 2007 May; 67(9):4364-72. PubMed ID: 17483350
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
[TBL] [Abstract][Full Text] [Related]
10. Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells.
Lin MF; Lee MS; Zhou XW; Andressen JC; Meng TC; Johansson SL; West WW; Taylor RJ; Anderson JR; Lin FF
J Urol; 2001 Nov; 166(5):1943-50. PubMed ID: 11586265
[TBL] [Abstract][Full Text] [Related]
11. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
12. The effect of a novel botanical agent TBS-101 on invasive prostate cancer in animal models.
Evans S; Dizeyi N; Abrahamsson PA; Persson J
Anticancer Res; 2009 Oct; 29(10):3917-24. PubMed ID: 19846929
[TBL] [Abstract][Full Text] [Related]
13. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
[TBL] [Abstract][Full Text] [Related]
14. Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation.
Sanders AJ; Parr C; Martin TA; Lane J; Mason MD; Jiang WG
J Cell Physiol; 2008 Sep; 216(3):780-9. PubMed ID: 18449907
[TBL] [Abstract][Full Text] [Related]
15. Significance of pituitary tumor transforming gene 1 (PTTG1) in prostate cancer.
Zhu X; Mao Z; Na Y; Guo Y; Wang X; Xin D
Anticancer Res; 2006; 26(2A):1253-9. PubMed ID: 16619532
[TBL] [Abstract][Full Text] [Related]
16. Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo.
Sanders AJ; Parr C; Davies G; Martin TA; Lane J; Mason MD; Jiang WG
J Exp Ther Oncol; 2006; 6(1):39-48. PubMed ID: 17228523
[TBL] [Abstract][Full Text] [Related]
17. Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase.
El Hilali N; Rubio N; Blanco J
Clin Cancer Res; 2005 Feb; 11(3):1253-8. PubMed ID: 15709196
[TBL] [Abstract][Full Text] [Related]
18. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro effect of baicalein on human prostate cancer cells.
Miocinovic R; McCabe NP; Keck RW; Jankun J; Hampton JA; Selman SH
Int J Oncol; 2005 Jan; 26(1):241-6. PubMed ID: 15586246
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
